Targeted HSP inhibitors have been evaluated in clinical trials against various cancers [121,122,123], but not for GBM, although preclinical studies have demonstrated efficacy of these agents in GBM models when administered alone or in combination with other therapeutics. Here, HSP90B2P is linked to glioblastoma.